We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information for clinicians and patients.
Information for patients, public and health care professionals.
This advice has been written by the Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG) at the request of the Medicines and Healthcare products Regulatory Agency (MHRA – UK regulator). It is in the form of questions, asked of...
Update on PIP silicone gel breast implants.
Update letter and guidance from Prof Sally Davies, Chief Medical Officer.
This document explains how to screen women with breast implants in the NHS Breast Screening Programme.
The latest advice from the NHS and plastic surgery experts is that women with PiP breast implants do not need to have them removed unless they have symptoms such as pain and tenderness.
This leaflet provides information about NHS breast screening for women with breast implants.
Information for healthcare professionals, patients, and the public.
Details of the toxicology testing carried out on PIP breast implants by the Medicines and Healthcare products Regualtory Agency (MHRA) between 2010 and 2012.
Updates from MHRA on the suspension of devices made by Silimed
Information for manufacturers of medical devices about reporting adverse incidents and field safety corrective actions to the MHRA.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 17 July 2024, approved the medicine capivasertib (Truqap) for patients with advanced hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer which has one or...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).